Uri Danon, CEO
Prior to joining Atox Bio, Mr. Danon was CEO of Epigenesis Ltd., a biotechnology company developing cell-therapy products. In his previous capacity as Product Development Manager in the Innovative Division of Teva Pharmaceuticals Ltd., Mr. Danon managed the development of Copaxone in PFS, a pharmaceutical product that achieved blockbuster sales. Mr. Danon brings to his current position 12 years of operational, business and management experience in pharmaceuticals and biotechnology. He holds an MBA from Bar-Ilan University and a BSc in Industrial Engineering from Tel Aviv University, Israel.

Dr. Raymond Kaempfer, Scientific Co-Founder and Chief Scientific Officer
Dr. Raymond Kaempfer is the Dr. Philip M. Marcus Professor of Molecular Biology and Cancer Research at the Hebrew University of Jerusalem, Israel. A molecular biologist at the Hebrew University-Hadassah Medical School, Dr. Kaempfer obtained his PhD from MIT (Massachusetts Institute of Technology, USA) and was a member of the Harvard University Biology faculty before joining the Hebrew University in the mid-1970s. Recognized worldwide as a leader in the field of superantigens, Dr. Kaempfer’s list of over 100 publications includes seminal contributions in the fields of molecular biology, gene regulation, cancer and molecular immunology.

Dr. Gila Arad, Scientific Co-Founder and R&D Director
Dr. Gila Arad is a molecular immunologist at the Hebrew University-Hadassah Medical School in Israel. Having earned her PhD from the Hebrew University of Jerusalem, Dr. Arad has been collaborating with Dr. Kaempfer for 20 years. Among her publications are important findings in the field of cytokine gene regulation and superantigen mode of action.